Advisory: Give yourself extra time when travelling by car to Toronto General Hospital, Princess Margaret Cancer Centre, or Toronto Rehab University Centre. City of Toronto construction on University Ave. may cause delays.
At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians,
staff, services and resources into 10 medical programs to meet the needs of our patients and help us make
the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in
Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international
source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community
and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one
of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases,
podcasts and more.
Senior Scientist, Princess Margaret Cancer CentreDirector, McEwen Stem Cell Institute
Dr. Gordon Keller is the Director of the McEwen Stem Cell Institute (formerly the McEwen Centre for Regenerative Medicine), a Senior Scientist at the Princess Margaret Cancer Centre and a Professor in the Department of Medical Biophysics at the University of Toronto. Dr. Keller is the premier researcher in the application of developmental biology-guided principles to the differentiation of pluripotent stem cells (PSCs) into therapeutically relevant cells, such as cardiomyocytes, hematopoietic cells and liver cells. Using developmentally guided approaches, his lab has successfully generated most of the cell types of the human heart and the human blood cell system from human pluripotent stem cells. His current research efforts are focused on translating these advances to the development of new cell therapies to treat cardiovascular and hematological diseases.
Dr. Keller earned his PhD in Immunology at the University of Alberta in 1979 and completed a Post-Doctoral Fellowship at the Ontario Cancer Institute in Toronto in 1983. Following his post-doctoral studies, he became a Member of the Basel Institute for Immunology in Switzerland where he worked for five years, then moved to Vienna, Austria where he accepted the post of Visiting Scientist at the Research Institute of Molecular Pathology. In 1990, Dr. Keller moved to the United States, working initially at the National Jewish Centre for Immunology and Respiratory Medicine in Denver, Colorado and then in the Department of Gene and Cell Medicine at the Mt. Sinai School of Medicine in New York where he was appointed Director of the Black Family Stem Cell Institute. He returned to Canada in 2006 to assume the position of Director of the McEwen Centre for Regenerative Medicine (now the McEwen Stem Cell Institute) at the University Health Network in Toronto.
Dr. Keller is also a founding Board member of the International Society of Stem Cell Research. In December 2016, Keller was named scientific co-founder of BlueRock Therapeutics, a biotechnology company that is developing pluripotent stem cell-based therapies to treat heart failure and Parkinson's disease. Dr. Keller received the Ogawa-Yamanaka Stem Cell prize in 2019 for his research on the differentiation of pluripotent stem cells and was a co-recipient of the 2021 Scientific Grand Prize from the Lefoulon-Delalande Foundation at the Institut de France for his contributions to our understanding of human cardiovascular development.
Learn more about Dr. Gordon Keller's work on UHN's Behind the Breakthrough podcast.
Modeling human multi-lineage heart field development with pluripotent stem cellsCell Stem Cell. 2022 Sep 1;29(9):1382-1401.e8.Yang D, Gomez-Garcia J, Funakoshi S, Tran T, Fernandes I, Bader GD, Laflamme MA, Keller G
Generation of mature compact ventricular cardiomyocytes from human pluripotent stem cellsNature Communications. 2021 May 26;12(1):3155.Funakoshi S, Fernandes I, Mastikhina O, Wilkinson D, Tran T, Dhahri W, Mazine A, Yang D, Burnett B, Lee J, Protze S, Bader GD, Nunes SS, Laflamme M, Keller G
Therapeutic correction of hemophilia A by transplantation of hPSC-derived liver sinusoidal endothelial cell progenitorsCell Reports. 2022 Apr 5;39(1):110621.Gage BK, Merlin S, Olgasi C, Follenzi A, Keller GM
Modeling human yolk sac hematopoiesis with pluripotent stem cellsJournal of Experimental Medicine. 2922 Mar 7; 219(3):e20211924Atkins MH, Scarfò R, McGrath KE, Yang D, Palis J, Ditadi A, Keller GM
Director: Dr. Gordon Keller
Administrative Assistant: Jonelle Martineau